Cargando…

Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomics

Conventionally, mouse hybridomas or well-plate screening are used to identify therapeutic monoclonal antibody candidates. In this study, we present an alternative to hybridoma-based discovery that combines microfluidics, yeast single-chain variable fragment (scFv) display, and deep sequencing to rap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adler, Adam S., Mizrahi, Rena A., Spindler, Matthew J., Adams, Matthew S., Asensio, Michael A., Edgar, Robert C., Leong, Jackson, Leong, Renee, Johnson, David S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680806/ https://www.ncbi.nlm.nih.gov/pubmed/28846506 http://dx.doi.org/10.1080/19420862.2017.1371386

Ejemplares similares

Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics
por: Adler, Adam S., et al.
Publicado: (2017)

Antibody repertoire analysis of mouse immunization protocols using microfluidics and molecular genomics
por: Asensio, Michael A., et al.
Publicado: (2019)

A natively paired antibody library yields drug leads with higher sensitivity and specificity than a randomly paired antibody library
por: Adler, Adam S., et al.
Publicado: (2018)

Preferential Identification of Agonistic OX40 Antibodies by Using Cell Lysate to Pan Natively Paired, Humanized Mouse-Derived Yeast Surface Display Libraries
por: Medina-Cucurella, Angélica V., et al.
Publicado: (2019)

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1
por: Li, Huifang, et al.
Publicado: (2022)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

Pocket ACEs: Discovering new function within an old player
por: Leong, Matthew, et al.
Publicado: (2023)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
por: Ou, Huilin, et al.
Publicado: (2022)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
por: Tritz, Zachariah P, et al.
Publicado: (2021)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Koyama, Shohei, et al.
Publicado: (2016)

Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade
por: Khan, Zia, et al.
Publicado: (2021)

Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Microbial mechanisms to improve immune checkpoint blockade responsiveness
por: Griffin, Matthew E., et al.
Publicado: (2022)

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
por: Zhang, Fei, et al.
Publicado: (2017)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
por: Wang, Ziming, et al.
Publicado: (2018)

Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
por: Lanzolla, Giulia, et al.
Publicado: (2019)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer
por: Kadam, Pournima, et al.
Publicado: (2020)

Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
por: Waaler, Jo, et al.
Publicado: (2020)

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
por: Tobin, Joshua W. D., et al.
Publicado: (2021)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
por: Su, Xiaofan, et al.
Publicado: (2022)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3lveug3apkqnj2i182kbqkqv98